RARE DISEASE
Allan-Herndon-Dudley syndrome
Allan-Herndon-Dudley syndrome
Allan-Herndon-Dudley syndrome
Synonyms: AHDS, MCT8 deficiency, Monocarboxylate transporter 8 deficiency, X-linked intellectual disability-hypotonia syndrome
Synonyms: AHDS, MCT8 deficiency, Monocarboxylate transporter 8 deficiency, X-linked intellectual disability-hypotonia syndrome
Synonyms: AHDS, MCT8 deficiency, Monocarboxylate transporter 8 deficiency, X-linked intellectual disability-hypotonia syndrome
Drug discovery
6
drugs
With orphan designations
Overview
Allan-Herndon-Dudley syndrome (AHDS) is a rare X-linked genetic disorder caused by mutations in the SLC16A2 gene, which disrupts thyroid hormone transport into the brain. This results in severe intellectual disability, motor dysfunction (hypotonia progressing to spasticity), and abnormal thyroid hormone levels (elevated T3, low T4). Affected males exhibit developmental delays, muscle hypoplasia, and characteristic facial features. Neurological deficits arise from cerebral hypothyroidism, while peripheral tissues experience thyrotoxicosis. Diagnosis relies on clinical findings, thyroid function tests, and genetic confirmation [1][6][12].
Burden
Severe disability: Most patients never walk or speak, requiring lifelong caregiver assistance [6][12].
Medical complications: Failure to thrive, respiratory infections, scoliosis, and cardiac arrhythmias [9][12].
Reduced lifespan: Mortality risk increases due to malnutrition and recurrent infections, though some survive into their 60s [1][12].
Economic impact: High costs associated with 24/7 care, specialized therapies, and frequent hospitalizations [4][19].
Therapies
Supportive care: Physical/occupational therapy, antispasmodics (e.g., baclofen), and seizure management [1][12].
Hormonal modulation: PTU/levothyroxine to reduce peripheral thyrotoxicosis [8]; thyroid hormone analogs (TRIAC, DITPA) bypass MCT8 to improve brain T3 availability [3][8].
Emerging therapies: AAV9-MCT8 gene therapy restored motor/cognitive function in preclinical models [2][18]; prenatal DITPA trials aim to mitigate developmental deficits [8].
Categories: rare endocrine diseases, rare genetic diseases, rare neurological diseases
Research Papers
122 drug discovery papers about Allan-Herndon-Dudley syndrome, with 2 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
122 drug discovery papers about Allan-Herndon-Dudley syndrome, with 2 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-09 | Central Thyroid Hormone Deprivation Disrupts Cortical Cilia and Oligodendrocyte Lineage in an Allan-Herndon-Dudley Syndrome Mouse Model.
Allan-Herndon-Dudley syndrome (AHDS) is an X-linked neurodevelopmental disorder caused by loss of the thyroid hormone (TH) transporter MCT8, resulting in central TH deprivation and disrupted cortical maturation, cognition, and motor control. MCT8/OATP1C1 double-knockout (dKO) mice faithfully model the human disease, recapitulating its postnatal hypomyelination, neuromotor impairment, and cortical defects. Yet, cell-type-specific pathologies underlying AHDS remain insufficiently defined. To uncover cellular perturbations by TH deprivation, we performed single-nucleus RNA sequencing on cortex and attached cerebral nuclei from P21 WT and dKO mice. Differential gene expression, trajectory, pseudotime and gene-set enrichment analyses, and NeuronChat-based cell-cell communication modeling were integrated with LC-MS/MS-based TH quantification, immunofluorescence, and RNAscope. In 48 clusters identified across cortical and striatal regions, we found increased numbers of GABAergic striatal D1 and D2 neurons in dKO mice, whereas mature oligodendrocytes were reduced. Trajectory analysis uncovered a bifurcation within the oligodendrocyte lineage, separating WT and dKO maturation paths and producing a dKO branch with gene profiles reminiscent of a stress-responsive, demyelination-prone state, despite largely preserved expression of core myelination genes. Trajectory analyses revealed shifted pseudotime states and distinct gene expression profiles in glutamatergic intratelencephalic and corticothalamic lineages of dKO mice. Differential gene expression patterns showed limited correspondence to Slc16a2 or Slco1c1 transcript levels but aligned strongly with published TH deprivation datasets, validating our findings and indicating that cellular perturbations are largely established by P21. Cell-cell communication analysis revealed a network imbalance favoring GABAergic over glutamatergic signaling, accompanied by altered neurexin-neuroligin interactions. In parallel, we identified a coordinated dysregulation of cilia-related genes, together with changes in cilia length and number. Our findings provide the first single-cell-level cortical map of AHDS brain pathology, revealing cilia defects, excitation-inhibition imbalance, differing pseudotime trajectories in glutamatergic neuronal populations and altered oligodendrocyte maturation, with actionable candidate genes such as Lama2, Litaf, and Dcc, as promising targets for future mechanistic and therapeutic exploration in AHDS. Slc16a2 and Slco1c1 transcript abundance alone did not predict cellular vulnerability, highlighting TH availability rather than transporter expression as key determinant of cell-type sensitivity and core mechanism for cortical network homeostasis.
2026-07-15 | Loss of Thyroid Hormone Transporters MCT8 and OATP1C1 in Mouse Oligodendroglia Cells Results in a Delayed Oligodendrocyte Maturation and Myelination.
Due to an impaired thyroid hormone (TH) transport across brain barriers, inactivation of the murine TH transporters Mct8/Oatp1c1 causes a profound TH deficiency of the CNS that greatly impacts neural development and function. Since oligodendrocyte maturation and myelination are dependent on local TH signaling, Mct8/Oatp1c1 double knockout (DKO) mice exhibit a persistent state of hypomyelination. Yet, to which extent Mct8/Oatp1c1 inactivation also affects TH transport into oligodendroglia cells has not been addressed. Here, we studied oligodendrocyte maturation and myelination in mice lacking Mct8/Oatp1c1 specifically in oligodendroglia lineage (OL) cells and compared their phenotype with that of control and DKO animals. Conditional Mct8/Oatp1c1 mutants were crossed with mice expressing constitutively Cre-recombinase under the control of the Olig2 promoter to inactivate both transporters in OL cells (so-called OL CKO mice). Neural maturation and myelination were assessed by immunofluorescence (IF) and fluorescence in situ hybridization (FISH) studies at different postnatal time points. Oligodendrocyte precursor cells (OPCs), premyelinating, and myelinating oligodendrocytes were visualized by coimmunolabeling. OL CKO mice exhibited normal serum TH concentrations and hypothalamic Trh transcript levels. Quantification of neuronal TH-target gene transcript levels (Rc3; Klf9; Pde10a) revealed no alterations. Abundance of myelin sheaths-related proteins Mbp and Cnp was significantly reduced in OL CKO mice at postnatal day P12 but reached normal levels at P21 and P120. Quantification of OPC, premyelinating, and myelinating oligodendrocytes disclosed a strongly reduced number of mature OL at P6 and P12, while cell numbers normalized in adult OL CKO mice. Inactivation of murine TH transporters Mct8/Oatp1c1 in OL cells causes a delayed oligodendroglia maturation and myelination. These findings highlight a physiologically relevant function of Mct8/Oatp1c1 in developmental oligodendrogenesis and myelin formation. In contrast to the persistent myelination defect seen in central hypothyroid DKO mice, OL CKO mice exhibit only a transient oligodendrocyte differentiation impairment and transient hypomyelination. These observations indicate the presence of additional, yet unknown, TH transporters that ultimately enable cellular TH entry into oligodendroglia cells even in the absence of Mct8/Oatp1c1.
2026-06-24 | Triiodothyroacetic acid exerts tissue-specific thyromimetic effects without tachycardia and hyperthermia in male mice.
Thyroid hormones regulate cardiovascular functions and energy homeostasis including thermogenesis through binding to nuclear thyroid hormone receptors. The thyroid hormone analogue 3,3',5-triiodothyroacetic acid (TRIAC) has recently emerged as a therapeutic candidate for thyroid hormone transporter deficiencies (Allan-Herndon-Dudley Syndrome) or thyroid hormone resistance β. Although TRIAC shows promise for these conditions, a comprehensive characterization focussing on heart and body temperature regulation has not been systematically performed in mice. As this knowledge is critical for determining its safety profile and therapeutic advantages over conventional thyroid hormone therapy, we administered TRIAC to wild-type mice for 14 days and assessed molecular (Realtime PCR, Western Blot, Immunoassays) and physiological responses (Infrared Thermography, Blood Pressure). TRIAC treatment reduced circulating thyroxine levels and induced robust upregulation of hepatic thyroid hormone-responsive genes including Dio1 and Me1, demonstrating classical thyromimetic activity. However, cardiovascular analysis revealed normal blood pressure and heart rate, and no signs of cardiac hypertrophy despite specific molecular changes in cardiac gene expression. On the metabolic level, we surprisingly did not observe any effect on brown fat thermogenesis or body temperature, while in muscle Ucp3 and Gpd2 were reduced. Taken together, our comparative in vivo analysis demonstrates variable TRIAC responsiveness across tissues. Under defined conditions, the drug produces defined metabolic responses while avoiding classical hyperthyroid manifestations such as tachycardia or hyperthermia, thus supporting its potential therapeutic use in thyroid hormone resistance conditions.
2026-06-22 | Reduced thyroid hormone transport in a human placental model with inhibited MCT8.
Maternal-to-fetal transfer of the thyroid hormone T4 is essential for prenatal neurodevelopment, but the transporter facilitating trans-placental T4 transport is unknown. Mutations in the thyroid hormone transporter MCT8 cause a neurodevelopmental and metabolic disorder which key clinical features can be ameliorated by the T3 analogue TRIAC. Should placental MCT8 be physiologically relevant, defective T4 transport across the placenta, which is fetal-derived tissue, could represent a hitherto unrecognized mechanism underlying MCT8 deficiency. We investigated the importance of MCT8 and the trans-placental transport of TRIAC using an ex vivo human placental perfusion setup. Uncomplicated term placentas were used for the ex vivo dual perfusion experiments to investigate the maternal-to-fetal transfer of T4 or TRIAC in the absence or presence of the MCT8 inhibitor silychristin. Samples were collected at various time points from both maternal and fetal circulations. T4 and rT3 concentrations in the perfused samples were measured using radio-immunoassay and TRIAC using LCMS/MS. In the presence of silychristin, maternal-to-fetal transfer of 100 nM T4 was reduced by ∼60% (4.2±1.2 nM fetal T4 in MCT8-inhibited placentas versus 10.6±0.6 nM fetal T4 in control placentas). TRIAC was efficiently transferred from the maternal to the fetal circulation. Our study (i) showed that MCT8 has a major role in maternal-to-fetal T4 transport, (ii) implies that disrupted placental transport of thyroid hormones may contribute to neurodevelopmental delays in MCT8 deficiency and (iii) indicated TRIAC is efficiently transported across the placenta, independent of MCT8, holding potential in mothers carrying fetuses with MCT8 deficiency.
2026-01-23 | Delineating the role of monocarboxylate transporter 8 (MCT8) in the context of neuroinflammation–mediated oligodendrocytopathy
Abstract Oligodendrocytes (OLs) myelinate central nervous system (CNS) axons and provide metabolic support to maintain axonal integrity. Thyroid hormone (TH) is a mitogen for oligodendroglial precursor cells (OPCs) maturation into myelinating OLs. Cellular uptake of TH is mediated by monocarboxylate transporter 8 (MCT8; encoded by slc16a2 ), and its dysfunction results in intracellular triiodothyronine (T3) deprivation, leading to hypomyelination and myelin degeneration during neuroinflammation. We showed that MCT8 expression is maintained in OPCs residing within the sub–ventricular zone (SVZ) throughout CNS development, suggesting a role during OL development. We identified MCT8 deficiency during neuroinflammatory and cuprizone demyelination models, as well as in secondary progressive multiple sclerosis (SPMS). These conditions were associated with dysregulated AKT–mTOR–PANK2 signaling and abrogated Co Enzyme A and lipid synthesis pathways in the CNS during myelin degeneration. Hence, neuroprotection during SPMS maybe achieved by overcoming MCT8 deficiencies in OLs.
2026-08-09 | Central Thyroid Hormone Deprivation Disrupts Cortical Cilia and Oligodendrocyte Lineage in an Allan-Herndon-Dudley Syndrome Mouse Model.
Allan-Herndon-Dudley syndrome (AHDS) is an X-linked neurodevelopmental disorder caused by loss of the thyroid hormone (TH) transporter MCT8, resulting in central TH deprivation and disrupted cortical maturation, cognition, and motor control. MCT8/OATP1C1 double-knockout (dKO) mice faithfully model the human disease, recapitulating its postnatal hypomyelination, neuromotor impairment, and cortical defects. Yet, cell-type-specific pathologies underlying AHDS remain insufficiently defined. To uncover cellular perturbations by TH deprivation, we performed single-nucleus RNA sequencing on cortex and attached cerebral nuclei from P21 WT and dKO mice. Differential gene expression, trajectory, pseudotime and gene-set enrichment analyses, and NeuronChat-based cell-cell communication modeling were integrated with LC-MS/MS-based TH quantification, immunofluorescence, and RNAscope. In 48 clusters identified across cortical and striatal regions, we found increased numbers of GABAergic striatal D1 and D2 neurons in dKO mice, whereas mature oligodendrocytes were reduced. Trajectory analysis uncovered a bifurcation within the oligodendrocyte lineage, separating WT and dKO maturation paths and producing a dKO branch with gene profiles reminiscent of a stress-responsive, demyelination-prone state, despite largely preserved expression of core myelination genes. Trajectory analyses revealed shifted pseudotime states and distinct gene expression profiles in glutamatergic intratelencephalic and corticothalamic lineages of dKO mice. Differential gene expression patterns showed limited correspondence to Slc16a2 or Slco1c1 transcript levels but aligned strongly with published TH deprivation datasets, validating our findings and indicating that cellular perturbations are largely established by P21. Cell-cell communication analysis revealed a network imbalance favoring GABAergic over glutamatergic signaling, accompanied by altered neurexin-neuroligin interactions. In parallel, we identified a coordinated dysregulation of cilia-related genes, together with changes in cilia length and number. Our findings provide the first single-cell-level cortical map of AHDS brain pathology, revealing cilia defects, excitation-inhibition imbalance, differing pseudotime trajectories in glutamatergic neuronal populations and altered oligodendrocyte maturation, with actionable candidate genes such as Lama2, Litaf, and Dcc, as promising targets for future mechanistic and therapeutic exploration in AHDS. Slc16a2 and Slco1c1 transcript abundance alone did not predict cellular vulnerability, highlighting TH availability rather than transporter expression as key determinant of cell-type sensitivity and core mechanism for cortical network homeostasis.
2026-07-15 | Loss of Thyroid Hormone Transporters MCT8 and OATP1C1 in Mouse Oligodendroglia Cells Results in a Delayed Oligodendrocyte Maturation and Myelination.
Due to an impaired thyroid hormone (TH) transport across brain barriers, inactivation of the murine TH transporters Mct8/Oatp1c1 causes a profound TH deficiency of the CNS that greatly impacts neural development and function. Since oligodendrocyte maturation and myelination are dependent on local TH signaling, Mct8/Oatp1c1 double knockout (DKO) mice exhibit a persistent state of hypomyelination. Yet, to which extent Mct8/Oatp1c1 inactivation also affects TH transport into oligodendroglia cells has not been addressed. Here, we studied oligodendrocyte maturation and myelination in mice lacking Mct8/Oatp1c1 specifically in oligodendroglia lineage (OL) cells and compared their phenotype with that of control and DKO animals. Conditional Mct8/Oatp1c1 mutants were crossed with mice expressing constitutively Cre-recombinase under the control of the Olig2 promoter to inactivate both transporters in OL cells (so-called OL CKO mice). Neural maturation and myelination were assessed by immunofluorescence (IF) and fluorescence in situ hybridization (FISH) studies at different postnatal time points. Oligodendrocyte precursor cells (OPCs), premyelinating, and myelinating oligodendrocytes were visualized by coimmunolabeling. OL CKO mice exhibited normal serum TH concentrations and hypothalamic Trh transcript levels. Quantification of neuronal TH-target gene transcript levels (Rc3; Klf9; Pde10a) revealed no alterations. Abundance of myelin sheaths-related proteins Mbp and Cnp was significantly reduced in OL CKO mice at postnatal day P12 but reached normal levels at P21 and P120. Quantification of OPC, premyelinating, and myelinating oligodendrocytes disclosed a strongly reduced number of mature OL at P6 and P12, while cell numbers normalized in adult OL CKO mice. Inactivation of murine TH transporters Mct8/Oatp1c1 in OL cells causes a delayed oligodendroglia maturation and myelination. These findings highlight a physiologically relevant function of Mct8/Oatp1c1 in developmental oligodendrogenesis and myelin formation. In contrast to the persistent myelination defect seen in central hypothyroid DKO mice, OL CKO mice exhibit only a transient oligodendrocyte differentiation impairment and transient hypomyelination. These observations indicate the presence of additional, yet unknown, TH transporters that ultimately enable cellular TH entry into oligodendroglia cells even in the absence of Mct8/Oatp1c1.
2026-06-24 | Triiodothyroacetic acid exerts tissue-specific thyromimetic effects without tachycardia and hyperthermia in male mice.
Thyroid hormones regulate cardiovascular functions and energy homeostasis including thermogenesis through binding to nuclear thyroid hormone receptors. The thyroid hormone analogue 3,3',5-triiodothyroacetic acid (TRIAC) has recently emerged as a therapeutic candidate for thyroid hormone transporter deficiencies (Allan-Herndon-Dudley Syndrome) or thyroid hormone resistance β. Although TRIAC shows promise for these conditions, a comprehensive characterization focussing on heart and body temperature regulation has not been systematically performed in mice. As this knowledge is critical for determining its safety profile and therapeutic advantages over conventional thyroid hormone therapy, we administered TRIAC to wild-type mice for 14 days and assessed molecular (Realtime PCR, Western Blot, Immunoassays) and physiological responses (Infrared Thermography, Blood Pressure). TRIAC treatment reduced circulating thyroxine levels and induced robust upregulation of hepatic thyroid hormone-responsive genes including Dio1 and Me1, demonstrating classical thyromimetic activity. However, cardiovascular analysis revealed normal blood pressure and heart rate, and no signs of cardiac hypertrophy despite specific molecular changes in cardiac gene expression. On the metabolic level, we surprisingly did not observe any effect on brown fat thermogenesis or body temperature, while in muscle Ucp3 and Gpd2 were reduced. Taken together, our comparative in vivo analysis demonstrates variable TRIAC responsiveness across tissues. Under defined conditions, the drug produces defined metabolic responses while avoiding classical hyperthyroid manifestations such as tachycardia or hyperthermia, thus supporting its potential therapeutic use in thyroid hormone resistance conditions.
2026-06-22 | Reduced thyroid hormone transport in a human placental model with inhibited MCT8.
Maternal-to-fetal transfer of the thyroid hormone T4 is essential for prenatal neurodevelopment, but the transporter facilitating trans-placental T4 transport is unknown. Mutations in the thyroid hormone transporter MCT8 cause a neurodevelopmental and metabolic disorder which key clinical features can be ameliorated by the T3 analogue TRIAC. Should placental MCT8 be physiologically relevant, defective T4 transport across the placenta, which is fetal-derived tissue, could represent a hitherto unrecognized mechanism underlying MCT8 deficiency. We investigated the importance of MCT8 and the trans-placental transport of TRIAC using an ex vivo human placental perfusion setup. Uncomplicated term placentas were used for the ex vivo dual perfusion experiments to investigate the maternal-to-fetal transfer of T4 or TRIAC in the absence or presence of the MCT8 inhibitor silychristin. Samples were collected at various time points from both maternal and fetal circulations. T4 and rT3 concentrations in the perfused samples were measured using radio-immunoassay and TRIAC using LCMS/MS. In the presence of silychristin, maternal-to-fetal transfer of 100 nM T4 was reduced by ∼60% (4.2±1.2 nM fetal T4 in MCT8-inhibited placentas versus 10.6±0.6 nM fetal T4 in control placentas). TRIAC was efficiently transferred from the maternal to the fetal circulation. Our study (i) showed that MCT8 has a major role in maternal-to-fetal T4 transport, (ii) implies that disrupted placental transport of thyroid hormones may contribute to neurodevelopmental delays in MCT8 deficiency and (iii) indicated TRIAC is efficiently transported across the placenta, independent of MCT8, holding potential in mothers carrying fetuses with MCT8 deficiency.
2026-01-23 | Delineating the role of monocarboxylate transporter 8 (MCT8) in the context of neuroinflammation–mediated oligodendrocytopathy
Abstract Oligodendrocytes (OLs) myelinate central nervous system (CNS) axons and provide metabolic support to maintain axonal integrity. Thyroid hormone (TH) is a mitogen for oligodendroglial precursor cells (OPCs) maturation into myelinating OLs. Cellular uptake of TH is mediated by monocarboxylate transporter 8 (MCT8; encoded by slc16a2 ), and its dysfunction results in intracellular triiodothyronine (T3) deprivation, leading to hypomyelination and myelin degeneration during neuroinflammation. We showed that MCT8 expression is maintained in OPCs residing within the sub–ventricular zone (SVZ) throughout CNS development, suggesting a role during OL development. We identified MCT8 deficiency during neuroinflammatory and cuprizone demyelination models, as well as in secondary progressive multiple sclerosis (SPMS). These conditions were associated with dysregulated AKT–mTOR–PANK2 signaling and abrogated Co Enzyme A and lipid synthesis pathways in the CNS during myelin degeneration. Hence, neuroprotection during SPMS maybe achieved by overcoming MCT8 deficiencies in OLs.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
6 orphan drug designations for Allan-Herndon-Dudley syndrome, including 1 approved therapy.
6 orphan drug designations for Allan-Herndon-Dudley syndrome, including 1 approved therapy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
3,5-diiodothyropropionic acid | small molecules | EMA | 2021-07-19 | — | Dexcel Pharma GmbH |
3,5-diiodothyropropionic acid | small molecules | FDA | 2020-07-28 | — | Dexcel Pharma Technologies Ltd. |
tiratricol | small molecules | FDA | 2019-01-16 | — | Rare Thyroid Therapeutics |
Tiratricol [Emcitate] | small molecules | EMA | 2017-11-08 | 2025-02-17 | Rare Thyroid Therapeutics International AB |
3,5-diiodothyropropionic acid | small molecules | EMA | 2013-10-07 | — | CATS Consultants GmbH |
3,5-diiodothyropropionic acid | small molecules | FDA | 2013-05-14 | — | Zarion Pharmaceuticals P/L |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.